Comparing antigenaemia - and microfilaraemia as criteria for stopping decisions in lymphatic filariasis elimination programmes in Africa
Published: 30 September 2022| Version 1 | DOI: 10.48765/nxq0-6562
Contributors:
, , , , , , , , , , , , , , Description
Data collected from participants at four separate timepoints in Cote d'Ivoire and Liberia identified by a unique participant ID. There are four timepoints collected from each country: Baseline, Follow-up Year 1, Follow-Up Year 2, and Follow-up Year 3. Each dataset includes the participant ID, gender, age, the microfilarae (MF) count collected through blood smear, and circulating filarial antigen (CFA) result from a strip test.
Files
Institutions
- Erasmus Universiteit Rotterdam
- University of Surrey
- University of Oxford
- Washington University in St. Louis
- University of Notre Dame
- University of Birmingham
- Centre Suisse de Recherches Scientifiques en Cote d'Ivoire
- University of South Florida
Categories
Medicine, Health Sciences, Parasitic Disease, Disease Modeling
Funders
- Bill and Melinda Gates FoundationUnited StatesGrant ID: OPPGH5342
- Nederlandse Organisatie voor Wetenschappelijk OnderzoekNetherlandsGrant ID: 016.Veni.178.023
- Bill and Melinda Gates FoundationUnited StatesGrant ID: OPP1184344
Additional Metadata for Digital Commons Data@Becker
| Keywords | Lymphatic Filariasis, Elimination, Mass Drug Administration, Mathematical Modelling, Albendazole, Endpoints, Ivermectin |
| Other Contributing Institutions | National Public Health Institute of Liberia, Ministry of Health and Social Welfare of Cote d'Ivoire |